Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 250 results for carcinoma

  1. Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

    Awaiting development [GID-TA11116] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. How many confirmatory diagnostic biopsies are carried out before definitive treatment, in people who have a clinical diagnosis of basal cell carcinoma and which different modalities used to treat basal cell carcinoma?

    have a clinical diagnosis of basal cell carcinoma and which different modalities used to treat basal cell carcinoma? Any...

    Research recommendation
    Published
    12 January 2016

  3. Taking a proportionate approach to technology appraisals

    Find out more about NICE's new proportionate approach to technology appraisals

  4. Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]

    In development [GID-TA10251] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683

    Awaiting development [GID-TA11053] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions) (IPG155)

    Evidence-based recommendations on photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions). This involves applying (or sometimes injecting) a photosensitising agent and using light to activate it, destroying the tumour cells.

    Interventional procedures guidance
    Published
    22 February 2006
    View recommendations

    Sections for IPG155

  7. Research on second-line treatments for transitional cell carcinoma of the urothelial tract is needed. It noted that the vinflunine studies were the only studies in patients with transitional cell carcinoma of the urothelial tract whose disease had progressed after platinum-based chemotherapy. It was noted that there is a lack of evidence for the relative effectiveness of treatment options at this stage in the pathway of care. It is recommended that studies be undertaken to investigate the relative safety and efficacy of second-line treatments for transitional cell carcinoma of the urothelial tract, particularly randomised controlled trials.

    Question Research on second-line treatments for transitional cell carcinoma of the urothelial tract is needed. It noted that the...

    Research recommendation
    Published
    9 June 2015

  8. Entrectinib for treating NTRK fusion-positive solid tumours (TA644)

    Evidence-based recommendations on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children over 12 years.

    Technology appraisal guidance
    Published
    12 August 2020
    View recommendations

    Sections for TA644

  9. Breast cancer (QS12)

    This quality standard covers the care of people with breast cancer after they have been referred to a specialist team. It includes the management of early (ductal carcinoma in situ and invasive), locally advanced and advanced breast cancer; recurrent breast cancer; and familial breast cancer. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    16 June 2016
    View quality statements

    Sections for QS12

  10. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736

    Awaiting development [GID-TA11076] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]

    Awaiting development [GID-TA11008] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)

    Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    21 February 2018
    View recommendations

    Sections for TA507

  13. Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

    Awaiting development [GID-TA11019] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Endoscopic submucosal dissection of oesophageal dysplasia and neoplasia (IPG355)

    Evidence-based recommendations on endoscopic submucosal dissection (ESD) of oesophageal dysplasia and neoplasia. This involves inserting a long camera through the mouth into the oesophagus to view the area and removing the abnormal part with special instruments.

    Interventional procedures guidance
    Published
    22 September 2010
    View recommendations

    Sections for IPG355

  15. Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)

    Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

    Evidence summary
    Published
    13 March 2013